We work Hard to get you posted with latest updates

http://We%20work%20Hard%20to%20get%20you%20posted%20with%20latest%20updates

Spend time learning about the different aspects of that topic from experts in the field.

ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody NSCLC Oncology oncology innovation oncology research Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory compliance targeted therapy

Unwrap our new Directory

http://Unwrap%20our%20new%20Directory

Directory

Home
Pharma
Bio-Pharma
MedTech
Veterinary
Cosmetics
Food
.Clinical
.Tech
.edu
.gov
M&A
.VC

Veeva Systems

Advertisement

cGxPJobs Banner

Veeva Acquires Ostro to Advance AI Engagement in Life Sciences

PLEASANTON, CA — March 10, 2026 Veeva Systems announced the acquisition of Ostro, a leading AI-driven brand engagement platform...

By cGxPwire Editor
March 12, 2026

Read More

Advertisement

cGxPJobs

Recent Posts

01

.Clinical

Innovent’s IBI343 Shows Strong Efficacy in Phase III Study, Eyes Regulatory Approval
June 5, 2026
02

M&A

CytomX and Regeneron Expand $4B Cancer Immunotherapy Alliance
June 5, 2026
03

Bio-Pharma

Lundbeck and Cradle Harness AI to Accelerate CNS Drug Discovery
June 5, 2026
04

Bio-Pharma

Australia Approves Amtagvi for Advanced Melanoma Care
June 4, 2026
05

Bio-Pharma

Alvotech Advances Key U.S. Biosimilars Toward FDA Review
June 4, 2026

Advertisement

Copyright © 2026 cGxP.wire | Made by 3styler

Directory

Home
Pharma
Bio-Pharma
MedTech
Veterinary
Cosmetics
Food
.Clinical
.Tech
.edu
.gov
M&A
.VC

Start typing and press Enter to search

Loading Comments...

Write a Comment...

Email (Required)

Name (Required)

Website